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ABSTRACT 
The presence of cell free fetal DNA in maternal circulation has allowed for the development 
of methods which allow for non-invasive detection of fetal chromosomal aneuploidies.  Non-
invasive prenatal testing (NIPT) thus avoids miscarriages due to invasive sampling of fetal 
material.  This test is rapidly adopted and revolutionizing prenatal diagnosis all over the 
world.  Despite the high accuracy of current NIPT testing, a base line false positive and false 
negative rate is remaining.   There are both biological and technical causes.  Biologically, the 
major challenge is the presence of mosaicism with a different constitution in the foetus as 
compared to the placenta. Technically, there are a number of potential problems: (1) The 
presence of maternal CNVs influences the Z-scores either positively or negatively and may, 
in turn, result in false positive or negative values; (2) The degradation and/or apoptosis of 
maternal cells would reduce the foetal fraction; (3) A low foetal fraction could cause false 
negative results; and, finally, the presence of factors in the mother which skew the average 
presence of the different chromosomes, e.g. maternal cancers or haematological 
malignancies or placental disorders may cause a larger variability of the counting statistics 
which can cause false positive z scores.  Here, we present a comprehensive analysis 
pipeline and software suite which addresses most of the technical challenges.  In addition, by 
in silico modeling, we visualize the inverse correlation between foetal fraction and read depth 
required for accurate trisomy detection.  Our approach resulted in 100% specificity and 
sensitivity for trisomy 21 and 18 detection (trisomy 21, n=17; trisomy 18, n=7) and the 
analysis pipeline is clinically implemented and accredited.  An overview of the clinical 
experience of the first 1000 samples will be provided. 
 
